戻る
Ventyx Biosciences Inc (VTYX)価格
VTYX 株価推移チャート
VTYX 収入
Ventyx Biosciences Inc
$13.89
0.21%
$0.03
終値： Jan 16, 16:00:00 GMT-5
$13.86
-0.14%
$-0.02
アフターマーケット：Jan 16, 20:00:00 GMT-5
主要データ
前終値
$13.86
始値
$13.87
当日レンジ
$13.85 - $13.9
52週レンジ
$0.783 - $25
取引高
1.7M
平均取引高
5.7M
1株当たり利益(TTM)
-1.50
配当利回り
--
時価総額
$989.7M
VTYXとは何ですか？
Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 83 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.